Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction
Naoki Okumura1, Yuji Sakamoto2, Keita Fujii1
1Department of Biomedical Engineering, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan.
Scientific Reports
|May 19, 2016
Summary
Tissue engineering offers a less invasive therapy for corneal endothelial dysfunction. Injecting cultured corneal endothelial cells with a Rho kinase (ROCK) inhibitor successfully regenerated the corneal endothelium in a primate model, showing promise for clinical application.
Area of Science:
- Ophthalmology
- Regenerative Medicine
- Tissue Engineering
Background:
- Corneal endothelial dysfunction leads to vision loss.
- Current treatments like donor corneal transplantation are invasive.
- Tissue engineering offers a promising alternative therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of cell-based therapy for corneal endothelial regeneration.
- To assess the use of Good Manufacturing Practice (GMP)-grade human corneal endothelial cells (HCECs).
- To investigate the role of Rho kinase (ROCK) inhibitors in improving cell engraftment.
Main Methods:
- Preclinical study in a primate model.
- Injection of cultured monkey corneal endothelial cells (MCECs) or GMP-grade HCECs into the anterior chamber.
- Co-administration with a Rho kinase (ROCK) inhibitor, Y-27632.
- Evaluation of corneal endothelium regeneration, cell engraftment, and adverse effects.
Main Results:
- Successful regeneration of the corneal endothelium following cell injection with Y-27632.
- GMP-grade HCECs demonstrated safety and efficacy without adverse effects.
- ROCK inhibition improved corneal endothelial cell (CEC) engraftment by overcoming substrate adhesion limitations.
Conclusions:
- Cell-based therapy using cultured CECs, enhanced by ROCK inhibition, is a viable strategy for treating corneal endothelial dysfunction.
- This approach shows potential as a clinically relevant and less invasive therapeutic modality.
- Further clinical trials are warranted to confirm efficacy and safety in human patients.
